Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07186842 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
A Phase 1 study of Advanced Solid Cancers, sponsored by BioNTech SE.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 245
- Enrollment target
- 4
- Study locations
NCT07186842: Recruiting Phase 1 study of Advanced Solid Cancers, sponsored by BioNTech SE.
NCT07186842 is a Phase 1 study of Advanced Solid Cancers that is actively recruiting participants, run by BioNTech SE. The registered enrollment target is 245 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (308% higher). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07186842, a Phase 1 study of Advanced Solid Cancers, is actively recruiting participants, sponsored by BioNTech SE.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 245 participants
- Enrollment target
- 4
- Study locations
Study Summary
The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are. The second goal of this study is to evaluate how well BNT329 works. This will be done by measuring the number of participants who respond to the treatment. The length of time where the tumor does not grow or spread will also be measured. The study will also evaluate how BNT329 moves into, through, and out of the body and how the treatment affects the body.
Primary Outcome
Per dose level.
Conditions Studied
Interventions
- DRUG BNT329
- DRUG CA19-9-targeting monoclonal antibody
Study Locations (4)
Other
- Hospital Universitario HM Sanchinarro - START Madrid CIOCC - Madrid
- Hospital Universitario Quironsalud Madrid - NEXT Oncology - Pozuelo de Alarcón
- The Royal Marsden Hospital - Sutton
Florida
- Florida Cancer Specialists - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2025-11-18 |
| Est. Completion | 2030-05 |
| Phase | Phase 1 |
What NCT07186842 shows while recruiting
NCT07186842 is an interventional study that assigns participants to a tested intervention. The registered 245 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (308% higher).
The record links to 1 condition, with Advanced Solid Cancers appearing as the primary indexed condition, and to 2 interventions - of which BNT329 is the first listed.
NCT07186842 reports a single indexed study location in Other, Florida.
Frequently Asked Questions
What is clinical trial NCT07186842 about?
NCT07186842 is a clinical study titled "A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9". The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are. The second goal of this study is to evaluate how well BNT329 works. This will be d...
What is the current status of trial NCT07186842?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 245 participants. The study started on 2025-11-18. Estimated completion is 2030-05.
What conditions does trial NCT07186842 study?
This clinical trial studies the following conditions: Advanced Solid Cancers.
What interventions are being tested in trial NCT07186842?
The interventions under investigation include: BNT329 (DRUG), CA19-9-targeting monoclonal antibody (DRUG).
Who is sponsoring clinical trial NCT07186842?
This trial is sponsored by BioNTech SE, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07186842 being conducted?
This trial has 4 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Cancers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07186842's enrollment target sits among peer trials
245 190th of 2000 higher than 1,810 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03645928 · 245 participants · Phase 2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- NCT04718168 · 245 participants · NA
GORE® ENFORM Biomaterial Product Study
- NCT05145127 · 245 participants · Phase 3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- NCT05446259 · 245 participants
Degenerative Cervical Myelopathy Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI